Navigation Links
Group of anti-diabetic drugs can significantly lower cancer risk in women with type 2 diabetes
Date:12/5/2013

Thursday, Dec. 5, 2013, Cleveland: A Cleveland Clinic-led study shows that a specific type of diabetes drug can decrease the risk of cancer in female patients with type 2 diabetes by up to 32 percent.

People with type 2 diabetes have a higher rate of cancer development and recurrence compared to the general population. This study published online today by the journal Diabetes, Obesity and Metabolism shows that widely prescribed anti-diabetes drugs can be linked to either an increased or decreased risk of cancer, depending on the type of medication prescribed.

A team of researchers led by Sangeeta Kashyap, M.D., an endocrinologist and associate professor of medicine at Cleveland Clinic's Endocrinology & Metabolism Institute, compared two groups of drugs commonly used to treat type 2 diabetes insulin sensitizers and insulin secretagogues. Insulin sensitizers lower blood sugar and insulin levels in the body by increasing the muscle, fat and liver's response to insulin. Insulin secretagogues lower blood sugar by stimulating pancreatic beta cells to make more insulin.

"What this study shows us is that using insulin secretagogues to increase insulin production correlates with an increased cancer risk in women with type 2 diabetes," said Kashyap. "By contrast, insulin sensitizers cut insulin levels and can decrease cancer growth. So, clearly, when prescribing anti-diabetic medications, it's important to consider the impact a drug has on fueling cancer growth."

In a retrospective analysis, researchers cross-indexed the electronic health record-based Cleveland Clinic Diabetes Registry (25,613 patients) with the histology-based tumor registry (48,051 cancer occurrences) over an 8-year period (19982006). More than 890 incident cancer cases were identified. The two most common cancers were prostate and breast, accounting for more than 25 percent of total cancer cases.

Study results show that the use of insulin sensitizers in female patients with type 2 diabetes was associated with a 21 percent decreased cancer risk compared with insulin secretagogues. Furthermore, the use of a specific insulin sensitizer, thiazolidinedione, was associated with a 32 percent decreased cancer risk in female patients compared with sulphonylurea, an insulin secretagogue. Results showed no significant difference in men.

The findings in this study contribute to existing research in the field on diabetic patients and their increased cancer risk. Further research is needed to examine the impact of oral diabetes therapy on cancer risk and development.


'/>"/>

Contact: Caroline Auger
augerc@ccf.org
216-636-5874
Cleveland Clinic
Source:Eurekalert

Related medicine news :

1. Physician Groups Call for Fewer Medical Tests
2. From herd immunity and complacency to group panic: How vaccine scares unfold
3. Study finds significant skull differences between closely linked groups
4. Diabetes Groups Issue New Guidelines on Blood Sugar
5. Small neural focus groups predict anti-smoking ad success
6. Group B streptococcal meningitis has long-term effects on childrens developmental outcomes
7. The Attilio Group’s TAG™-Simply Faster Taps SmartSales To Accelerate Its Expansion Into National Reach
8. Infants cant distinguish between large and small groups
9. Rush joins elite group of institutions with accredited research programs
10. The Casey Group's Sales Navigator Wins 2012 Best Mobility App in the New Jersey Technology Council's Mobile Application Competition
11. Artisan Business Group hosts EB-5 Conference in California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
Breaking Medicine Technology: